Omnicell, Inc. (NASDAQ:OMCL) Shares Sold by South Dakota Investment Council

South Dakota Investment Council reduced its holdings in shares of Omnicell, Inc. (NASDAQ:OMCL) by 53.1% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 9,727 shares of the company’s stock after selling 11,000 shares during the quarter. South Dakota Investment Council’s holdings in Omnicell were worth $433,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Pier Capital LLC acquired a new position in shares of Omnicell during the third quarter valued at about $5,859,000. Royce & Associates LP acquired a new stake in Omnicell during the 3rd quarter worth about $811,000. Geode Capital Management LLC grew its stake in Omnicell by 0.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,104,745 shares of the company’s stock valued at $48,176,000 after purchasing an additional 2,877 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its holdings in shares of Omnicell by 750.5% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 294,037 shares of the company’s stock valued at $12,820,000 after purchasing an additional 259,463 shares during the period. Finally, Intech Investment Management LLC purchased a new position in shares of Omnicell in the third quarter worth about $753,000. 97.70% of the stock is currently owned by hedge funds and other institutional investors.

Omnicell Stock Performance

NASDAQ OMCL opened at $39.83 on Tuesday. The stock has a market capitalization of $1.84 billion, a price-to-earnings ratio of 147.52, a PEG ratio of 7.53 and a beta of 0.78. The stock has a 50-day moving average of $42.96 and a 200 day moving average of $43.89. The company has a current ratio of 1.37, a quick ratio of 1.22 and a debt-to-equity ratio of 0.13. Omnicell, Inc. has a twelve month low of $25.12 and a twelve month high of $55.74.

Omnicell (NASDAQ:OMCL) last announced its earnings results on Thursday, February 6th. The company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%. Sell-side analysts anticipate that Omnicell, Inc. will post 1.09 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on OMCL. Wells Fargo & Company dropped their target price on Omnicell from $49.00 to $40.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th. Craig Hallum upped their price objective on shares of Omnicell from $45.00 to $64.00 and gave the company a “buy” rating in a report on Thursday, October 31st. Barclays raised their target price on shares of Omnicell from $39.00 to $58.00 and gave the stock an “equal weight” rating in a report on Thursday, October 31st. Bank of America decreased their target price on shares of Omnicell from $54.00 to $46.00 and set a “neutral” rating for the company in a research report on Monday, January 6th. Finally, JPMorgan Chase & Co. increased their price target on Omnicell from $37.00 to $44.00 and gave the stock a “neutral” rating in a research report on Thursday, November 21st. Five analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $52.33.

Insiders Place Their Bets

In other news, Director Mark W. Parrish sold 12,000 shares of Omnicell stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $47.30, for a total value of $567,600.00. Following the sale, the director now directly owns 58,427 shares of the company’s stock, valued at $2,763,597.10. The trade was a 17.04 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 2.64% of the stock is currently owned by company insiders.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.